CompletedNot Applicable

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

United States100 participantsStarted 2008-11-23

Plain-language summary

The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.

Who can participate

Age range1 Day – 3 Weeks

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Infants with birth weights between 500 and 1500 grams admitted to the NICU with any of the following lines will be eligible for inclusion in this study
✓. umbilical arterial line (UAL)
✓. umbilical venous line (UVL)
✓. peripheral arterial line (PAL)
✓. peripheral long line (PLL)
✓. central venous line (CVL)
✓. Each eligible subject will be randomized to receive either standard of care or silver alginate dressing. Dressings will be changed every 7 days in accordance to current facility protocols.

What they're measuring

The primary objective of this trial is to assess the efficacy of silver alginate dressing in reducing central line infections in VLBW infants

Timeframe: 2 years

Trial details

NCT IDNCT00964093

SponsorBaylor Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-08-25

View on ClinicalTrials.gov More Central Line Bloodstream Infections trials